Research and development services BA230121 titled self assembling vaccine platform
Active Definitive Contract Awarded Last action
- Contract number
- HT942523C0078
- Awardee
-
Hexamer Therapeutics Inc. UEI MK8HSFMVB647
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $3,928,061
Award facts
- Opportunity
-
- DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research Department of Defense Dept. of the Army -- USAMRAA Special Notice · HT942523SBAA1 · Posted Sep 29, 2022
- Contract value 100% obligated
- $3,928,061.02 Current and potential, with all options
- Completion date 89% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Pullman, WA 99163, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | -$0 | |
| Original award | $3,928,061 |
About this award
The Defense Health Agency awarded a $3.93 million definitive contract to Hexamer Therapeutics Inc. for research and development services on September 29, 2023, under a firm fixed-price structure with no set-aside.
The contract funds development of a self-assembling, molecular carrier vaccine platform intended for deployment during an infectious disease pandemic, under the U.S. Army Medical Research and Development Command's mission to provide medical solutions for service members and the general public. The originating solicitation, posted as a Broad Agency Announcement, invited competitive research proposals across all entity types in basic research, applied research, advanced technology development, and advanced component development. Place of performance is Pullman, WA. The contract extends through March 31, 2027.
Quick answers
Who was awarded contract HT942523C0078?
HT942523C0078 was awarded to Hexamer Therapeutics Inc. by Defense Health Agency (Department of Defense) on September 29, 2023.
How much is contract HT942523C0078 worth?
The government has obligated $3,928,061 on HT942523C0078.
Was contract HT942523C0078 competed?
The extent of competition for HT942523C0078 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award